Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oral Vancomycin in Recurrent PSC Post-Liver Transplant
NCT03046901Withdrawn
- Sponsor
- Ochsner Clinic Foundation
- Start
- Dec 2016
- Primary completion
- Feb 2019
- Modality
- Cyclic Peptides, Antimicrobial Peptides, Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of vancomycin in Primary Sclerosing Cholangitis (PSC), sponsored by Ochsner Clinic Foundation. Primary endpoint: Liver Function Test at 12 weeks. Planned start Dec 2016; status: withdrawn.
02
Drugs
vancomycin
03
Conditions
Primary Sclerosing Cholangitis (PSC)
Beyond the preview
Go deeper on NCT03046901.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03046901.